Background: We investigated the impact of Helicobacter pylori eradication on the expression of Ki67, p53, and cyclin D1 in patients diagnosed with chronic gastritis and intestinal metaplasia, utilizing the immunohistochemistry (IHC) method. Methods: The immunoexpression of Ki67, p53, and cyclin D1 in the gastric mucosa was analyzed in 26 patients with chronic gastritis, intestinal metaplasia, and confirmed H. pylori infection, as well as 10 patients with normal gastric histology and no H. pylori infection. The assessments were performed both before and after H. pylori eradication. Results: Successful eradication of H. pylori resulted in a significant reduction in the immunoexpression of Ki67, p53, and cyclin D1 in the majority of patients compared to pre-treatment. High immunoreactivity for Ki67, p53, and cyclin D1 was observed before eradication in 13 (50%), 4 (15.4%), and 9 (34.6%) patients, respectively. Following H. pylori eradication, none of the patients exhibited high immunoreactivity for these markers. Additionally, negative immunoreactivity for Ki67, p53, and cyclin D1 was noted in 21 (80.7%), 21 (80.7%), and 12 (46.1%) patients, respectively, with statistically significant P values of 0.005, 0.02, and 0.004. Conclusion: The eradication of H. pylori in patients with chronic gastritis and intestinal metaplasia leads to a significant regression in the immunoreactivity of Ki67, p53, and cyclin D1. This suggests the potential for reversing precancerous changes in the gastric mucosa through timely treatment.
Toosi et al. (Fri,) studied this question.